ゾコーバ錠 125mg

第 2 部 (モジュール 2) : CTD の概要 (サマリー)

2.7 臨床概要

2.7.5 参考文献

塩野義製薬株式会社

目次

2.7.5 参考文献 3

2.7.5 参考文献

＜2.7.1 生物製剤学試験及び関連する分析法＞

該当なし.

＜2.7.2 臨床薬理試験＞

1. John VA, Shotton PA, Moppert J, Theobald W. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report. Br J Clin Pharmacol 1985; 19(S2): 203S-6S.
2. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008; 47(10): 669-80.
3. 日本医療薬学会．医療現場における薬物相互作用へのかかわり方ガイド．2019 年 11 月 14 日.
4. Hisaka A, Kusama M, Ohno Y, Sugiyama Y, Suzuki H. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet 2009; 48(10): 653-66.
5. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007; 46(8): 681-96.
6. Oda K, Yamano K, Otsuka Y. In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure. Biopharm Drug Dispos 2015; 36(5): 265-74.
7. Garnett C, Bonate PL, Dang Q, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 2018; 45(3): 383-97.
8. Garnett C, Bonate PL, Dang Q, et al. Correction to: Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 2018; 45(3): 399.
9. 厚生労働省医薬・生活衛生局医薬品審査管理課. 医薬品開発と適正な情報提供のための薬物相互作用ガイドライン．平成 30 年 7 月.
10. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry. In vitro Drug Interaction Studies—Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. January 2020.
11. European Medicines Agency. Committee for Human Medicinal Products. Guideline on the Investigation of Drug Interactions. January 2013.

＜2.7.3 臨床的有効性＞

1. 厚生労働省．新型コロナウイルス感染症 (COVID-19) 診療の手引き・第 9 版．令和 5 年 2 月10 日.
2. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv 2021; 2021-06.
3. National Institutes of Health. Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19. September 2022.

4. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2022; 2(1), e13-e22.
5. 広島県健康福祉局．広島県新型コロナウイルス感染症版 J-SPEED データ等からの知見 第 7波データ分析．https://www.mhlw.go.jp/content/10900000/000975398.pdf ＜アクセス日：2023 年5月 26 日＞
6. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drug and Biological Products for COVID-19 Prevention or Treatment. September 2020.
7. Townsley H, Carr EJ, Russell TW, et al. Non-hospitalised, vaccinated adults with COVID-19 caused by Omicron BA. 1 and BA. 2 present with changing symptom profiles compared to those with Delta despite similar viral kinetics. medRxiv 2022.
8. デジタル庁．ワクチン接種記録システム (VRS)．新型コロナワクチンの接種状況．https://info.vrs.digital.go.jp/dashboard/ ＜アクセス日：2023 年 5 月 26 日＞
9. 株式会社シー・アール・シー．特異的 IgE 抗体のクラス判定の解釈は？https://www.crc-group.co.jp/crc/q_and_a/59.html ＜アクセス日：2023 年 5 月 26 日＞

＜2.7.4 臨床的安全性＞

該当なし．